We recognize the need to develop novel approaches to package therapeutic agents to enable direct transfer into cells to access targets, while avoiding immune reaction and degradation mechanisms that interfere with successful delivery. This treatment gap drives Vesigen’s development of our novel ARMMs (ARRDC1 Mediated Microvesicles) technology, a class of extracellular vesicles that permits novel therapeutic paradigms in hard-to-access tissue types.
With a seasoned team, we intend to expediently advance our portfolio and to chart a clear path to the clinic . Our team has decades of experience leading drug discovery and development activities in preclinical and clinical settings. Supported by our top-tier investors and a prominent scientific advisory board, Vesigen is prepared to deliver on the promise of ARMMed therapeutics.
Vesigen Therapeutics
790 Memorial Drive
Suite 103
Cambridge, MA 02139
